Assessing no-reflow in STEMI patients after tirofiban treatment
Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
This study is testing if the drug tirofiban can help prevent no-reflow in patients with a severe heart attack who have had a procedure to open their blocked arteries.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Kafrelsheikh University Academic / other |
| Locations | 1 site (Kafr ash Shaykh, Kafrelsheikh) |
| Trial ID | NCT06966674 on ClinicalTrials.gov |
What this trial studies
This study evaluates the occurrence of no-reflow in patients experiencing ST-segment-elevation myocardial infarction (STEMI) after receiving intracoronary administration of the glycoprotein IIb/IIIa inhibitor tirofiban. The research focuses on patients who have undergone primary percutaneous coronary intervention (PCI) to open blocked coronary arteries. By investigating the effectiveness of tirofiban in preventing no-reflow, the study aims to improve patient outcomes following acute coronary events.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are experiencing STEMI.
Not a fit: Patients with contraindications for tirofiban or those with severe comorbidities such as end-stage liver disease or renal failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for preventing no-reflow in STEMI patients, potentially reducing adverse cardiovascular events.
How similar studies have performed: While there have been studies exploring the use of glycoprotein IIb/IIIa inhibitors in STEMI, the specific focus on no-reflow in this context may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old. * Both sexes. * Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain \>30 minutes with ST-segment elevation of \>1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block. Exclusion Criteria: * Treatment with thrombolytic drugs in the previous 24 hours. * Known malignancy. * Thrombocytopenia. * End-stage liver disease. * Cardiogenic shock. * Renal failure with glomerular filtration\<30 ml/min. * Contraindication for the use of tirofiban.
Where this trial is running
Kafr ash Shaykh, Kafrelsheikh
- Kafrelsheikh University — Kafr ash Shaykh, Kafrelsheikh, Egypt (Recruiting)
Study contacts
- Study coordinator: Mohammed A Hammad, MD
- Email: drhammad879@gmail.com
- Phone: 00201015928694
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.